Ignite Creation Date:
2024-05-05 @ 11:37 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00092521
Status:
COMPLETED
Last Update Posted:
2015-09-25
First Post:
2004-09-23
Brief Title:
Cervical Intraepithelial Neoplasm CIN-Warts Efficacy Trial in Women GardasilV501-013COMPLETED
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6- 11- 16- and 18-Related CIN AIS and Cervical Cancer and HPV 6- 11- 16- and 18-Related External Genital Warts Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia Vulvar Cancer and Vaginal Cancer in 16- to 23-Year-Old Women
Status:
COMPLETED
Status Verified Date:
2015-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of the study is to determine if GARDASIL V501 with four components is able to prevent cervical cancer cervical dysplasia including Cervical Intraepithelial Neoplasia CINAny Grade and Adenocarcinoma In Situ AIS and genital warts
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2004_081 | None | None | None |